Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes that works by activating satiety receptors in the hypothalamus and slowing gastric emptying
If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage. Reference: The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study by Regina Castaneda, Dima Bechenati, Elif Tama, Rene Rivera Gutierrez, Maria A Espinosa, Jose Villamarin, Tamim I Rajjo, Andres Acosta, Stephanie Faubion, Chrisandra Shufelt and Maria D Hurtado Andrade, 22 January 2026, The Lancet Obstetrics, Gynaecology, & Womens Health
Skin Lightening with Confidence: Achieve the skin you desire without worry
Strategic supplementation fills the gaps